Gallup released the results of a poll that shows 72% of Americans see foreign trade as an opportunity for economic growth.
The mainstream media (ABC, NBC, CBS, FOX, CNN, The New York Times) and those of the Democrat and Republican establishments have not educated the public about what China has done to our country. (Read More….)
Here is a Chinese company that can produce CAR-T cells at the rate of 10,000 patients per year. Mass producing CAR-T cells is always a challenge because each CAR-T cell treatment has to be produced for a particular patient.
CBMG aims for large-scale CAR-T capacity
Scientists are working to reduce the toxicity caused by CAR T cells and they are making progress.
CAR T cells in leukaemia
20 Major Inventions Nobody Knows NASA Invented – NASA Technology Documentary
Folks, the more research I do on CAR-T cells the more I realize that this technology is a game changer; however, it does have some limitations as Dr. Chaudhary discusses.
Dr. Chaudhary on Short-Term and Long-Term Future of CAR T Cells
Ron Paul continues to forecast a collapse of the US economy even in light of the election of President Trump.
Ron Paul said that Federal Reserve policy has set the country up for economic collapse, and though the central bank has been very creative in making the impossible work, and putting off financial (Read More….)
February 19, 2017: President Trump on Thursday, February 16, 2017, signed legislation ending a key Obama administration coal mining rule. The bill ends the Office of Surface Mining’s Stream Protection Rule, a regulation to protect waterways from coal mining waste. Source: http://thehill.com/policy/energy-environment/319938-trump-signs-bill-undoing-obama-coal-mining-rule
SunCoke Energy should benefit from the bill President Trump signed on February (Read More….)
March 14, 2016: 3-D Systems Corp reports Q4 2015 EPS of $0.19 versus $0.04 estimate. Revenue also beat coming in at $183 million versus $174 million estimate… (Read More….)
A weekly Saturday night financial show that attempts to predict market direction for the week ahead by looking at a variety of technical and fundamental indicators.
This week’s show includes a sermon about why people are always fussing and fighting.
February 17, 2017: Celgene announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) ß-1a (Avonex).
SUNBEAM evaluated two (Read More….)
Overnight Analyst Actions:
GRUB Overweight Pacific Crest/Keybanc
HAIN Hold Argus HTZ Underperform Credit Suisse First Boston TTMI Neutral JPMorgan Chase and Co
Overnight Headlines By Ticker:
ABBV AbbVie Inc.
2/17 08:00 Announces $5B increase to stock repurchase program (4.9% of market cap)
ABT Abbott Laboratories
February 17, 2017: Fluor Corp reports Q4 EPS of $0.82 versus the $0.80 estimate. Revenue also beat coming in at $4.99 billion versus the $4.83 billion estimate.
David Thomas Seaton, CEO of Fluor, said, “In 2016 we set the foundation to expand our presence in the markets we serve. This includes our acquisition of (Read More….)
February 17, 2017: Medtronic announced Japan regulatory approval for the world’s smallest pacemaker, the Micra(TM) Transcatheter Pacing System (TPS). Japan’s Pharmaceuticals and Medical Device Agency (PMDA) granted approval for Micra based on positive data from the Medtronic Micra TPS Global Clinical Trial, which enrolled 744 patients and evaluated the safety and efficacy of the device (Read More….)
February 17, 2017: JPMorgan Chase and Co reiterates Broadcom with an Overweight rating and a price target of $230. Based on JPMorgan’s research efforts and triangulating recent industry news, they believe that Broadcom, working with Apple, has developed a chip solution that will be used to power the wireless charging functionality on the iPhone platform. (Read More….)
February 16, 2017: AMN Healthcare Services reports Q4 EPS of $0.62 versus the $0.55 estimate. Revenue also beat coming in at $487.9 million versus the $477 million estimate. Adjusted EBITDA came in at $60.9 million which is up +29.9% YoY.
January 22, 2017: Benchmark Company initiates coverage of AMN AMN Healthcare with a Buy (Read More….)
Overnight Analyst Actions:
CACI Buy Seaport Global Securities
BMA Neutral JPMorgan Chase and Co REGN Neutral Goldman Sachs & Co SONS Neutral DA Davidson & Co TECK Hold Deutsche Banc Securities
Overnight Headlines By Ticker:
ACM Aecom Technology
2/15 17:37 Prices $1B in senior unsecured (Read More….)
February 16, 2017: Sell Orexigen Therapeutics for a 157% win in 36 days! Congratulations if you were able to make money on this trade.
January 25, 2017: Orexigen Therapeutics announced that Laboratorios Farmaceuticos Rovi has launched Mysimba in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult (Read More….)
February 16, 2017: Huntington Ingalls Industries reports Q4 EPS of $3.67 versus the $2.48 estimate. Revenue also beat coming in at $1.92 billion versus the $1.85 billion estimate.
CEO Michael Petters said, “Exceptional execution on mature programs at Ingalls lessened the impact of the ongoing transition between programs at Newport News and drove the (Read More….)
February 15, 2017: Adeptus Health’s stock has beautiful rising money flow. The stock plunged nearly -70% after the company missed the third-quarter earnings. There is also a lawsuit claiming that Adeptus Health engaged in widespread predatory billing practices and that Adeptus Health’s predatory billing practices subjected the Company to numerous known but undisclosed risks, such (Read More….)
February 15, 2017: Elon Musk appears to be part of Democrat attempts to discredit and destroy President Trump’s Administration. Musk tweets, “The Muslim immigration ban is not right… Regarding govt policy, there are often things that happen that many people don’t agree with. This is normal for a functioning democracy. They rarely warrant a public (Read More….)
February 15, 2017: Valeant Pharmaceuticals gets FDA approval for Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or (Read More….)
February 15, 2017: Editas Medicine confirms patent office decision favorable to Broad Institute in CRISPR Interference. Editas Medicine’s stock is up more than +27% on the news.
The U.S. Patent and Trademark Office (USPTO) issued a favorable decision today in the CRISPR interference between the University of California, the University of Vienna, Emmanuelle Charpentier and (Read More….)